In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...
Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...
On December 13, Truist Securities upgraded Sangamo’s stock from Hold to Buy, setting a price target ... the introduction of the QIAprep& CRISPR Kit and CRISPR Q-Primer Solutions, which ...
CRISPR Therapeutics AG (CRSP) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $43.42, moving -1.83% from the previous trading session. CRISPR Therapeutics (CRSP) saw its shares surge in the last session ...
Qiagen NV (NYSE:QGEN) recently enhanced its product offerings with the introduction of the QIAprep& CRISPR Kit and CRISPR Q-Primer ... QGEN) with a Buy rating and a price target of $54.
Qiagen NV (NYSE:QGEN) recently enhanced its product offerings with the introduction of the QIAprep& CRISPR Kit and CRISPR Q-Primer ... QGEN) with a Buy rating and a price target of $54.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback